hero section gradient
17 handpicked stocks

Onshoring Stocks: Could New Tariffs Boost Manufacturing?

The Trump administration has imposed new tariffs on pharmaceuticals, trucks, and furniture to spur domestic production. This creates an investment opportunity in U.S.-based construction, engineering, and industrial companies poised to benefit from the push to build new manufacturing plants.

Author avatar

Han Tan | Market Analyst

Published on September 29

Your Basket's Financial Footprint

Market cap breakdown for a basket focused on onshoring and industrial infrastructure companies.

Key Takeaways for Investors:
  • Large-cap weighting generally brings stability and lower volatility; returns aren't guaranteed and values can fall.
  • Use as a core portfolio holding for broad industrial exposure, not a speculative high-growth position.
  • Expect steady long-term value rather than explosive short-term gains; monitor sector risks and diversification needs.
Total Market Cap
  • IESC: $7.80B

  • EME: $28.67B

  • FLR: $6.82B

  • Other

About This Group of Stocks

1

Our Expert Thinking

New tariffs on pharmaceuticals, trucks, and furniture are creating powerful incentives for companies to build manufacturing facilities in the U.S. rather than import goods. This policy shift could drive a significant wave of domestic capital investment, benefiting the entire industrial value chain from construction to equipment suppliers.

2

What You Need to Know

This group focuses on cyclical opportunities tied to increased domestic manufacturing investment. The companies span engineering, construction, raw materials, and industrial equipment - all essential components needed to build and outfit new production facilities across America.

3

Why These Stocks

These companies were handpicked by professional analysts for their strategic positioning in the onshoring value chain. Each firm is positioned to capture revenue from the policy-driven push to relocate manufacturing operations to the U.S., representing a targeted approach to this emerging trend.

Why You'll Want to Watch These Stocks

🏭

Manufacturing Renaissance

New tariffs are creating the strongest incentive in decades for companies to build factories on American soil. This could spark a multi-year construction and investment boom.

Policy-Driven Catalyst

Unlike typical market cycles, this opportunity is backed by direct government policy designed to reshape where companies manufacture their products.

🎯

Value Chain Winners

From concrete suppliers to industrial equipment makers, these companies are positioned at every stage of the factory-building process, capturing multiple revenue streams.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Beverage Stocks: What's Next After Coca-Cola's Pivot

Beverage Stocks: What's Next After Coca-Cola's Pivot

Coca-Cola is discontinuing its historic Minute Maid frozen products to focus on faster-growing beverage categories. This strategic shift highlights a broader investment opportunity in companies leading the market's transition toward healthier, more convenient, and functional drinks.

Factory Automation Stocks | Rising Labor Costs Trend

Factory Automation Stocks | Rising Labor Costs Trend

Volkswagen's recent agreement with the UAW signals a new era of rising labor costs for foreign automakers in the U.S. This theme focuses on companies poised to benefit as the industry increases investment in factory automation and robotics to enhance productivity.

Blood Thinner Breakthrough Explained | Market Overview

Blood Thinner Breakthrough Explained | Market Overview

Bayer's successful Phase III trial for its new blood thinner has demonstrated a significant reduction in stroke recurrence. This breakthrough positions the company favorably against competitors and highlights an investment opportunity in the evolving landscape of cardiovascular treatments.

Frequently Asked Questions